Jamile Shammo, MD:We have a 72-year-old man who presented to his physician with symptoms of fatigue and night sweats, and was found to have splenomegaly on exam that measured about 6 cm below the left costal margin. And his CBC demonstrated a little bit of leukocytosis with a white blood cell count of 22,000, hemoglobin of 9.7, and platelet count was perfectly normal at 255,000. The patient underwent a bone marrow biopsy to evaluate the etiology of the anemia and leukocytosis, and the morphology demonstrated clusters of megakaryocytes and 3+ reticulin fibrosis. There was also molecular testing forJAK2V617F mutation, which turned back positive. At this point, the patient was diagnosed with primary myelofibrosis.
This case demonstrates an older gentleman who is greater than 65 years of age, and here, I’m going to focus the case relative to the International Prognostic Scoring System, which is an important method for us to estimate survival of this patient population. So, it turns out that patients who are over the age of 65 are given a point, essentially, toward that score. The second point is that the hemoglobin of 9.8 represents another point because the presence of anemia seems to also be a negative prognostic indicator in this patient population. And the third is simply the presence of constitutional symptoms. In this situation, it’s night sweats. So, if you added 1 point for each variable, then you have an IPSS score of 3 and this means that this patient has high-risk myelofibrosis. That translates, essentially, to a 2-year survival for this particular patient.
This is not an unusual way for patients with myelofibrosis to present. I have seen a variety of patients who come in with, again, various clinical presentations. This would be 1 possibility. About one-quarter of patients with myelofibrosis may not have any symptoms actually, believe it or not, but then 75% of them will. Other patients may present mainly with very high platelet count, leukocytosis, significant anemia, and some may only present with anemia. I think when you look at the CBC abnormalities in myelofibrosis, it tends to be the most variable of all MPNs. In the beginning, they may end up with cytosis and a little bit of anemia. As the disease goes on, you end up with more manifestations of bone marrow failure and cytopenias.
Transcript edited for clarity.
June 2016
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More